ZHANG Xiaodan,WANG Ruiqin,LIU Lu,et al.Meta-analysis of the efficacy and safety of Saccharomyces boulardii versus Bifidobacterium triple live bacteria in the treatment of pediatric diarrhea[J].ZHONGGUO YAOFANG,2024,35(02):226-230.
ZHANG Xiaodan,WANG Ruiqin,LIU Lu,et al.Meta-analysis of the efficacy and safety of Saccharomyces boulardii versus Bifidobacterium triple live bacteria in the treatment of pediatric diarrhea[J].ZHONGGUO YAOFANG,2024,35(02):226-230. DOI: 10.6039/j.issn.1001-0408.2024.02.18.
Meta-analysis of the efficacy and safety of Saccharomyces boulardii versus Bifidobacterium triple live bacteria in the treatment of pediatric diarrhea
and Bifidobacterium triple live bacteria in the treatment of pediatric diarrhea.
METHODS
2
Retrieved from PubMed, Embase, the Cochrane Library, CBM, Wanfang data, CNKI and VIP, randomized controlled trials (RCTs) about
S. boulardii
(
S. boulardii
group) versus Bifidobacterium triple liver bacteria (Bifidobacterium group) were collected. After screening the literature, extracting data and evaluating the quality, meta-analysis was performed by using RevMan 5.3 software.
RESULTS
2
A total of 9 RCTs were included, involving 898 patients. Results of meta-analysis showed there was no statistical significance in total response rate [OR=1.69, 95%CI (0.93, 3.09),
P
=0.09], duration of diarrhea [MD=-1.39, 95%CI (-3.35, 0.57),
P
=0.16], the time of abdominal pain disappearance [MD=0.09, 95%CI(-0.87, 1.05),
P
=0.86] or the incidence of adverse reactions [OR=0.65, 95%CI (0.05, 8.03),
P
=0.74]. The number of stools in
S. boulardii
group was significantly less than Bifidobacterium group [MD=-0.91, 95%CI (-1.80, -0.02),
P
=0.04]. The results of subgroup analysis showed that the duration of diarrhea in children with antibiotic-associated diarrhea in
S. boulardii
group was significantly shorter than Bifidobacterium group (
P
<0.05).
CONCLUSIONS
2
The efficacy and safety of
S. boulardii
are similar to those of Bifidobacterium in the treatment of diarrhea, but
S. boulardii
is better than Bifidobacterium in terms of stool number, the duration of diarrhea in children with antibiotic-associated diarrhea.
关键词
布拉氏酵母菌双歧杆菌三联活菌儿童腹泻疗效安全性Meta分析
Keywords
Bifidobacterium triple live bacteriapediatric diarrheaefficacysafetymeta-analysis
references
罗光全. 小儿腹泻病治疗新进展[J]. 包头医学,2014,38(2):73-76.
LUO G Q. New progress in the treatment of diarrhea in children[J]. J Baotou Med,2014,38(2):73-76.
LIU S Y,YANG Z H,YUAN R,et al. Application of probiotics and intestinal flora balance outlook to infantile diarrhea[J]. West J Tradit Chin Med,2014,27(12):94-95.
ZHANG W N,LI M T. Clinical observation on the treatment of diarrhea with fever in children with triple viable bacteria of Saccharomyces boulardii and bifidobacterium[J]. Matern Child Health Care China,2023,38(5):843-846.
LI X Y,ZHANG X H,ZHANG Z H,et al. The clinical outcome of Saccharomyces boulardii and triple viable bifidobacterium in the treatment of rotaviral gastroenteritis for children[J]. Jilin Med J,2018,39(2):279-281.
胡会,张婷. 儿童腹泻病的诊治策略[J]. 上海医药,2022,43(16):3-6,34.
HU H,ZHANG T. Diagnosis and treatment strategies of diarrhoea in children[J]. Shanghai Med Pharm J,2022,43(16):3-6,34.
ZENG X T,ZHANG Y G,KWONG J S,et al. The metho-dological quality assessment tools for preclinical and clinical studies,systematic review and meta-analysis,and clinical practice guideline:a systematic review[J]. J Evid Based Med,2015,8(1):2-10.
ZHANG J W,WAN S,GUI Q Q. Comparison of safety,effectiveness and serum inflammatory factor indexes of Saccharomyces boulardii versus Bifidobacterium triple viable in treating children with chronic diarrhea:a rando-mized trial[J]. Transl Pediatr,2021,10(6):1677-1685.
ZHOU Q F. Clinical analysis of different methods in the treatment of antibiotic-associated diarrhea in children with bronchopneumonia[J]. J Front Med,2017,7(12):44-45.
ZHANG Y H. Clinical observation on the treatment of antibiotic-associated diarrhea in children with microecological preparations[J]. Clin Res Pract,2017,2(6):116-117.
LI L. Significance of Saccharomyces boulardii sachets in the treatment of children with dyspepsia diarrhea[J]. Chin J Mod Drug Appl,2020,14(20):141-143.
XIAO Z H,LI B. Saccharomyces boulardii combined with bifid-triple viable capsules in children with viral diarrhea[J]. Chin Gen Pract,2013,16(32):3119-3120.
HU Y X. Efficacy comparison between Saccharomyces boulardii sachets and triple viable bifidobacterium capsule in the treatment of respiratory tract infection with antibiotic-associated diarrhea[J]. J Pediatr Pharm,2014,20(4):22-24.
LIAO H,YU J H,DUAN S W. Efficacy and safety analysis of microecological agents in the treatment of children’s diarrhea[J]. Chin J Urban Rural Enterp Hyg,2017,32(6):101-102.
CUI L. Efficacy of microecological preparation on the changes of intestinal flora and clinical symptoms for children with diarrhea[J]. Tibet Med,2017,38(3):7-10.
左林军. 急性腹泻的常见原因[J]. 家庭生活指南,2023,39(8):193-194.
ZUO L J. Common causes of acute diarrhea[J]. Fam Life Guide,2023,39(8):193-194.
HUI J,BAI Q Q,YANG Y,et al. In vitro evaluation of the probiotic characteristics and function of Saccharomyces cerevisiae boulardii[J]. J Liaoning Univ Nat Sci Ed,2022,49(4):370-376
WANG Z M,TANG W H,WANG H T,et al. Therapeutic effect of Saccharomyces boulardii powder on antibiotic-associated diarrhea and its influence on serum TNF-α and IL-6 levels[J]. Zhejiang J Integr Tradit Chin West Med,2019,29(8):644-646.
ZHENG Y L. Clinical observation on the adjuvant treatment of rotavirus enteritis in children with Saccharomyces boulardii[J]. Med Forum,2022,26(34):38-40,43.